Lung Cancer Studies Find Gains in Survival, Recovery

New findings and patient stories highlight how lung cancer care spans prevention, treatment and recovery. At the 2026 World Conference on Lung Cancer, eight-year ADAURA results showed adjuvant osimertinib was associated with higher survival and lower risk of death for patients with resected EGFR-mutated non-small cell lung cancer; real-world data also suggested that stopping treatment early may worsen outcomes. A Kansas City man with stage IV lung cancer driven by a rare mutation entered remission after coordinated specialist care that included targeted medication and radiation. Experts say screening can reduce lung cancer deaths, while noting that current annual low-dose CT recommendations focus on people ages 50 to 80 with a substantial smoking history, and that early disease often causes no symptoms. Recovery also involves life beyond treatment: one study found 55% of working-age patients returned to work within a month of minimally invasive surgery, though many were unsure they could sustain it. In a separate trial, nurse-led support after surgery improved patients’ confidence and self-management, but did not significantly improve several physical and quality-of-life measures compared with standard care.